Anti-Migratory Effect of Dipotassium Glycyrrhizinate on Glioblastoma Cell Lines: Microarray Data for the Identification of Key MicroRNA Signatures

Gabriel Alves Bonafé1,2†, Jéssica Silva dos Santos1,2†, Anna Maria Alves de Piloto Fernandes3, Jussara Vaz Ziegler4, Fernando Augusto Lima Marson1,2†, Thalita Rocha5†, Patricia de Oliveira Carvalho3† and Manoela Marques Ortega1,2*†

1 Laboratory of Cell and Molecular Tumor Biology and Bioactive Compounds, Post Graduate Program in Health Science, São Francisco University, Bragança Paulista, São Paulo, Brazil, 2 Laboratory of Human and Medical Genetics, Post Graduate Program in Health Science, São Francisco University, Bragança Paulista, São Paulo, Brazil, 3 Multidisciplinary Research Laboratory, Post Graduate Program in Health Science, São Francisco University, Bragança Paulista, São Paulo, Brazil, 4 Verdi Cosmetics Limited Liability Company, Joaopoli, São Paulo, Brazil, 5 Post Graduate Program in Biomaterials and Regenerative Medicine, Faculty of Medical Sciences and Health, Pontifical Catholic University of São Paulo, Sorocaba, São Paulo, Brazil

The nuclear factor kappa B (NF-κB) pathway has been reported to be responsible for the aggressive disease phenomenon observed in glioblastoma (GBM). Dipotassium glycyrrhizinate (DPG), a dipotassium salt of glycyrrhizic acid isolated from licorice, has recently demonstrated an anti-tumoral effect on GBM cell lines U87MG and T98G through NF-κB suppression by IRAK2- and TRAF6-mediated microRNA (miR)-16 and miR-146a, respectively. Thus, the present study aimed to evaluate the expression profiles of miRNAs related to NF-κB suppression in T98G GBM cell line after DPG exposure using miRNA microarray (Affymetrix Human miRNA 4.0A), considering only predicted miRNAs as NF-κB regulator genes. Additional assays using U251 and U138MG cells were performed to validate the array results. DPG cytotoxicity was determined by (4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay, and cellular apoptosis was quantified by DNA fragmentation and terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) assay. The anti-proliferative effect was observed by cell proliferation and wound-healing assays, and the sphere formation assay examined whether DPG reduced stem cell subpopulation formation. The most over-expressed miRNAs were miR-4443 and miR-3620. The cytotoxic effect of DPG in U251 and U138MG was observed with an IC50 of 32 and 20 mM for 48 h, respectively. The IC50 of each cell line was used in all further assays. DPG treatment-induced apoptosis is observed by DNA fragmentation and increased TUNEL-positive cells. Cell proliferation and wound-healing assays showed an anti-proliferative and anti-migratory effect by DPG on the evaluated cell lines. In addition, DPG treatment led to a 100% reduction in sphere formation. The qPCR results in U251 and U138MG cells showed that DPG increased miR-4443 (2.44 vs. 1.11, p-value = 0.11;
INTRODUCTION

Glioblastoma (GBM) cells have a high capacity to invade and infiltrate normal surrounding brain tissue aggressively, hindering complete surgical resection (1). In addition, GBM cell tumors are very resistant to radiation and cytotoxic chemotherapy (2). GBM molecular subtyping, over the past two decades, has provided predictions of evolution, common disease pathways, and better treatment options (3–8). In addition, single-cell RNA sequencing revealed that multiple subtypes could exist within a single tumor, underscoring the substantial inter- and intra-tumor heterogeneity of GBM (9). MicroRNAs (miRNAs), a class of small non-coding RNA species, have critical functions across various biological processes associated with the pathogenesis of GBM (10). The miR expression signatures also characterize the phenotypic diversity of GBM subclasses through their ability to regulate developmental growth and differentiation (10, 11). Moreover, miRNAs have been previously proven to be promising diagnostic biomarkers in GBM (11–13).

Dipotassium glycyrrhizinate (DPG, C42H60K2O16), a dipotassium salt of glycyrrhizic acid (C42H62O16) isolated from licorice (Glycyrrhiza glabra), has recently demonstrated an anti-tumoral effect on GBM cell lines U87MG and T98G through a decrease of proliferation and an increase of apoptosis. In addition, DPG anti-tumoral effect seems to be related to nuclear factor kappa B (NF-kB) pathway suppression by IRAK2- and TRAF6-mediated miR-16 and miR-146a, respectively (14). In fact, one study supported the role of miRNAs in NF-kB regulation (15).

In the present study, the expression profile of miRNAs in T98G GBM cells, a temozolomide (TMZ)-resistant cell line, after DPG exposure was obtained using microarrays. Interestingly, the most over-expressed miRNAs were miR-4443 and miR-3620. Additional cellular studies using other GBM cell lines were performed to validate the array results. Moreover, DPG decreased the viability and sphere formation of the cultured stem cell-enriched populations of established GBM cell lines.

MATERIALS AND METHODS

Cell Culture and Treatments

U87MG, T98G, U251, and U138MG were kindly donated by Dr. Adriana da Silva Santos Duarte, Hemocenter, University of Campinas, Campinas, São Paulo, Brazil, and were cultured at 37°C in Dulbecco’s modified Eagle’s medium (DMEM) high glucose supplemented with 10% fetal calf serum (FCS) and 1% penicillin/streptomycin (Cultilab, Campinas, São Paulo, Brazil) at 37°C in a 5% CO2 atmosphere. For all experiments, the cells were seeded and grown for 72 h before the experimental treatments. The cells were passaged by Trypsin 0.25% (Cultilab) until the seventh passage after thawing.

DPG (chemical abstracts service number 68797-35-3) was obtained from Verdi Cosmetics LLC (Joanópolis, São Paulo, Brazil). For the cell line treatments, DPG was diluted in DMEM to prepare a 2,000-μM stock solution. All treatment assays were performed in the presence of 10% FCS and 1% P/S.

Ultraperformance Liquid Chromatography

The composition of DPG was determined by ultraperformance liquid chromatography–mass spectrometry using an Acquity UPLC system (Waters Co., Milford, MA, USA) coupled with an Acquity TQD mass spectrometer (Micromass; Waters Co.) as described in Franco et al. (16).

Determination of Cellular Metabolic Activity (Cell Viability)

Adherent GBM cells (U251 and U138MG) were seeded in 96-well flat-bottomed tissue culture plates (0.2 × 10⁶ cells/plate). After 24 h of incubation at 37°C in a 5% CO₂ environment, various concentrations (5, 8, 12, 15, 18, 20, 24, 28, 32, and 36 mM) of DPG were used to treat the GBM cell lines based on a previous study (14). The cells were cultured for 24, 48, and 72 h prior to (4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide incubation (Sigma, St. Louis, MO, United States). The cells were incubated for 4 h at 37°C in a 5% CO₂ environment. Following incubation, formazan crystals were solubilized with 100 μL of dimethyl sulfoxide. Cell viability was determined by
measuring the optical density at 550 nm using a microplate spectrophotometer (Thermo Fisher, Waltham, MA, USA). The cell survival rates were expressed as percentages of the value of normal cells. Untreated control cells were analyzed in all experiments, and all DPG dose treatments were performed in triplicate.

**Determination of DPG Effects on Cell Viability**

U251 and U138MG cells (0.4 × 10⁶ cells/well) were cultured in 24-well tissue culture plates for 24 h at 37°C in a 5% CO₂ environment and further exposed to 32 and 20 mM of DPG, respectively. The cells were washed in phosphate-buffered saline (PBS), and the viable cells were counted by trypan blue dye exclusion assay for 4 days. Untreated cells were used as a control, and the experiments were performed in triplicate.

**Evaluation of the Effect of DPG on Cell Death by DNA Fragmentation**

U251 and U138MG cells were cultured in 6-well tissue culture plates for 24 h at 37°C in a 5% CO₂ environment and further exposed to 32 and 20 mM of DPG for 48 and 72 h, respectively. The TMZ-resistant U251 was also exposed for 96 h. DNA was isolated using lithium chloride extraction (17). The purity of DNA was analyzed in a spectrophotometer at 260/280 nm, and the ratio was confirmed to be between 1.7 and 1.9. DNA samples were then electrophoresed on 1.5% agarose gel and visualized with ethidium bromide staining under ultraviolet illumination.

**Evaluation of DPG Effect on Cell Death by TUNEL Assay**

U251 and U138MG cells were cultured in 96-well tissue culture plates for 24 h at 37°C in a 5% CO₂ environment and further exposed to 32 and 20 mM of DPG for 72 h, respectively. Cellular apoptosis was evaluated after treatment with DPG by *in situ* terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) assay using *in situ* cell death detection kit, fluorescein (Roche Applied Science, Mannheim, Germany), according to the manufacturer’s protocols. Apoptotic indexes were calculated by scoring four randomly selected fields and counting the number of apoptotic cells over the total of viable cells, representing a ratio compared to untreated cells. The cells were directly analyzed under a fluorescence microscope (Axio Vert. A1 ZEISS, Germany).

**Wound Healing Assay**

U251 and U138MG cells were seeded in 6-well plates (1 × 10⁶ cells/well) and grown overnight at 37°C in a 5% CO₂ environment to confluence. The monolayer of cells was scratched with a 200-mL pipette tip to create a wound, and the plates were washed twice with PBS and cultured with DPG (32 mm and 20 mM, respectively). Afterward, cells migrating from the leading edge were photographed at 0, 24, 48, and 72 h under an inverted microscope (Axio Vert. A1 ZEISS). Untreated cells were used as a control. The distance of the scratch closure was examined using ImageJ software (National Institutes of Health, Bethesda, MD, United States). Each value is derived from the same selected fields, and results are expressed as the mean of migrating cell numbers per field.

**Sphere-Cultured Stem Cell-Enriched GBM Populations**

U251 and U138MG cells (1 × 10⁴ cells/well) were cultured at 37°C in a 5% CO₂ environment in serum-free DMEM/F12 supplemented with N₂ supplement (StemCell, Vancouver, Canada) containing epidermal growth factor (20 ng/mL) (Peprotech, Ribeirão Preto, São Paulo, Brazil), basic fibroblast growth factor (20 ng/mL) (Peprotech), and 1% penicillin/streptomycin (120 mg/mL) (Thermo Fisher) for at least 6 days. For the subsequent DPG treatment (32 and 20 mM, respectively), 75-µm neuro-spheres were cultured for 24 and 48 h. Cells without DPG were cultured as controls. Cells were observed and photographed under an inverted microscope (Axio Vert. A1 ZEISS).

**miRNA and Gene Expression Arrays**

miRNA expression profiles were conducted in T98G cell line DPG exposure (24 mM; 48 h of DPG treatment) (14) and control cells. Analyses were performed using Affymetrix® GeneChip miRNA 2.0 array (Affymetrix, Santa Clara, CA, USA), which detects 2,578 known human miRNAs (miRBase v.15; Affymetrix). Total RNA was labeled with FlashTag Biotin HSR, hybridized with the arrays, then washed with PBS, stained, and scanned according to Affymetrix GeneChip Command Console software. The miRNA QC Tool software (Affymetrix) was used for data summarization, normalization, and quality control.

**Identification of miRNA Target Genes**

The analysis of miRNA differential expression profile was performed considering only 91 miRNAs previously selected and predicted as regulators of genes involved in the NF-κB pathway (Supplementary Table S1). Conventional online programs, including miRanda (http://www.microrna.org), TargetScan (http://www.targetscan.org), and Findtar (http://bio.sz.tsinghua.edu.cn), were used to predict the targets of miRNAs. To identify the most likely targets, mRNA and miRNA expression data obtained on the same biological samples using Microsoft Excel tools were integrated. Two-fold upregulated miRNA and corresponding 2-fold downregulated mRNA targets were selected for further investigation.

**Total RNA Isolation**

For the U87MG and T98G cells, the half-maximal inhibitory concentration (IC50) used is based on a previous study using DPG as a therapeutic compound in GBM cell lines (14). Total RNA was isolated from U87MG, T98G, U251, and U138MG cells after DPG exposure (18, 24, 32, and 20 mM for 48 h, respectively) and control cells using TRIzol® reagent (Thermo Fisher), according to the manufacturer’s instructions. Total RNA quantification was performed using the ND-1000 spectrophotometer (Nanodrop; Thermo Fisher).
Validation of miRNA and mRNA Expression Levels

cDNA conversion was performed using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA). qPCR was performed on a 7500 Fast Real-Time PCR system (Applied Biosystems) using SYBR-Green PCR Master Mix (Applied Biosystems). Each sample was examined in triplicate, and the expression of each gene was normalized by control gene expression (GAPDH) and calculated by applying the 2^{-ΔΔCt} method (18). The expression value of each gene was represented as fold change. The primer sequences used for amplification by qPCR with SYBRGreen dye (Applied Biosystems) are as follows: CD209 5'-CATGTCTAACTCCCAGCGG-3' (sense) and 5'-GAAA GTCCCCATCCAGGTGAAG-3' (anti-sense), TNC 5'-CACT ACAC AGGCC AAGATCCAG-3' (sense) and 5'-TCGT GTCT CCATT CAGC ATTG-3' (anti-sense), and GAPDH (forward) 5'-CCAC TIG ATTTTGGAGGGAT-3 and (reverse) 5'-GCA CCGT CAAG GCTGAGAAC-3'.

miRNA expression analysis was validated using the MicroRNA Assay kit (Applied Biosystems), which incorporates a target-specific stem-loop reverse transcription primer to provide specificity for mature miRNA target. U6 served as an endogenous control for the normalization of RNA input. Specific primers for mRNA expression analysis and the endogenous control were provided by Thermo Fischer (miR-4443: assay 463010_mat; miR-3620: assay CTAK3MT; and U6: assays 001973 and 03928990_g1). The specificity of the PCR products was tested by dissociation curves. Relative values of transcripts were calculated using the equation 2^{-ΔΔCt}, where ΔCt is equal to the difference in threshold cycles for target and reference genes. Each experiment was performed in triplicate.

Statistical Analysis

A two-tailed T-test was performed for all two sets of numerical data (treated and non-treated cells), and P-value ≤0.05 was considered statistically significant. The results are expressed as mean ± SD from experiments repeated at least three times. Statistical analysis was performed using the Statistical Package for the Social Sciences software (IBM SPSS Statistics for Macintosh, version 27.0).

RESULTS

DPG Analysis by Liquid Chromatography

Mass spectrometry (UPLC-QTOF, Waters) was applied to evaluate the presence of DPG in the sample used for the present study. The signals from [M-H] - and [M-2H] - anions as well as the mass measurement accuracy and the adequacy of the simulated isotopic standard for [M-H] - ion confirmed the presence of the DPG (Supplementary Figure S1A).

DPG Inhibits Cell Viability and Proliferation

The antitumor effect of DPG was evaluated by using two GBM cell lines (U251 and U138MG). Based on these findings, the cytotoxic effect of DPG was time and dose dependent, and the IC50 in U251 and U138MG was 32 and 20 mM for 48 h, respectively (Figures 1A, D). For all further assays, IC50 was adopted. Moreover, it was observed that cells presented nuclear morphological changes after 48 h of DPG treatment (Figures 1B, E). Furthermore, cell proliferation assay showed a significantly anti-proliferative effect by DPG on the same cell lines starting after 24 h of treatment (p-value = 2.6 × 10^{-5} and p-value = 2.2 × 10^{-9}, respectively) until 96 h later (p-value = 2.8 × 10^{-15} and p-value = 2.6 × 10^{-15}, respectively) (Figures 1C, F).

DPG Induces Apoptosis

To investigate cellular apoptosis, DNA fragmentation was quantified by TUNEL assay. As expected, DPG was also able to induce cellular apoptosis by DNA fragmentation (Figures 2A, C), which was confirmed by increased TUNEL-positive cells when compared to untreated cells (Figures 2B, D), mostly on the U138MG cell line (p-value = 0.023).

DPG Inhibits Invasion and Migration

Furthermore, to investigate the effect of DPG on the migration ability of U251 and U138MG, both cell lines were treated with DPG for 24, 48, and 72 h, and a wound-healing motility assay was performed simultaneously. The results showed that cells exposed to DPG migrated significantly slower than DPG-free control cells starting after 24 h of treatment (p-value = 1 × 10^{-5} and p-value = 1 × 10^{-5}, respectively) until 96 h later (p-value = 2 × 10^{-5} and p-value = 9 × 10^{-7}, respectively) (Figures 3A, B).

DPG Effect on GBM Stem-Like Cells

The phenotypic plasticity of cancer cells grown as neurospheres to elucidate the influence of DPG on GBM stem-like cells was also investigated. Thus, it was observed that DPG promoted a 100% reduction in neurosphere formation compared to untreated cells, starting after 24 h of DPG exposure (p-value ≤ 0.05) (Figures 3C, D), characterizing DPG as an antitumor compound.

Identification of miRNAs With Differential Expression

Global miRNA expression changes in T98G cells were evaluated after 48 h of treatment with 24 mM of DPG. No treated T98G cells were evaluated as control. A total of 11 miRNAs with DE-miRNAs were identified after comparing DPG-treated and control samples (among 91 predicted miRNAs as NF-kB regulator genes) (Supplementary Figure S2A). The number of upregulated and downregulated DE-miRNAs is shown in Tables 1, 2, respectively. Furthermore, a new analysis was performed considering the expression values, mRNA volume, and target genes predicted to be involved in GBM pathogenesis, and most DE-miRNAs were found to be miR-4443 and miR-3620 (Supplementary Figure S2B) and their respective target genes CD209 and TNC.
Validation of miRNA and mRNA Expression Levels

The expression of both miRNAs and their predicted target genes was evaluated by qPCR using U87MG, T98G, U251, and U138MG cell lines after exposure to DPG. Untreated cells were used as controls. In accordance with the global analysis, the mean mRNA expression level was significantly higher in DPG-treated T98G cells when compared to control cells for miR-4443 (2.44 vs. 1.17, p-value = 0.03) (Figure 4A) and miR-3620 (7.50 vs. 1.19, p-value = 0.007) (Figure 4B). In addition, qPCR showed that DPG increased the level of miR-4443 (2.44 vs. 1.11, p-value = 0.11; 8.27 vs. 1.25, p-value = 0.04; 1.64 vs. 1.00, p-value = 0.05) (Figure 4A) and miR-3620 expression (1.66 vs. 1.00, p-value = 0.03; 8.47 vs. 1.00, p-value = 0.03; 2.08 vs. 1.04, p-value = 0.05) in U251, U138MG, and U87MG cell lines (Figure 4B).

On the other hand, the CD209 and TNC expression levels were lower in DPG-treated cells when compared to controls (Figures 4C, D). Thus, decreased CD209 (0.06 vs. 1.07, p-value = 0.007; 0.32 vs. 1.04, p-value = 0.002; 0.44 vs. 1.11, p-value = 0.03; 0.49 vs. 1.07; p-value = 0.04) (Figure 4C) and TNC (0.24 vs. 1.03, p-value = 0.03; 0.05 vs. 1.15, p-value = 0.03; 0.20 vs. 1.03, p-value = 0.001; 0.39 vs. 1.06; p-value = 0.01) (Figure 4D) mRNA levels were observed in U87MG, T98G, U251, and U138MG when compared to control cells.

DISCUSSION

In the present study, we demonstrated first that DPG, under in vitro conditions, was able to significantly reduce the number of viable cells in GBM cell lines U251 and U138MG, inhibiting cell growth and adhesion. This finding corroborates with previous results using the GBM U87MG and T98G cell lines (14). In addition, this previous study has suggested alterations in miRNA expression after DPG treatment in GBM cell lines U87MG and T98G (14), which were able to modulate NF-kB genes. Thus, here a global analysis evaluated potentially over-expressed miRNAs responsible for the NF-kB pathway in GBM cells. The choice of T98G for array analysis was based on hypermethylated MGMT promoter and mutated P53 gene. In fact, cell lines with a hypermethylated MGMT promoter and mutated P53 gene appeared more resistant to the action of TMZ than the ones with wild-type P53 (19) since p53 protein is fundamental in regulating the cell cycle arrest and the entry in the apoptotic
Besides this, it was observed previously that the effect of DPG on T98G decreased cell proliferation and increased migration and invasion at a concentration of 24 mM (14).

Few studies have focused on miRNAs involved in the NF-κB pathway, which is known as continuously active (22) in GBM (14, 23–28). Thus, the large-scale global approach evaluated 91 miRNAs previously selected and predicted as regulators of genes involved in the NF-κB pathway in T98G lineage exposed to DPG action. Among the 11 DE-miRNAs reported in the present study, none has been previously evaluated in GBM cells. Besides, 2 miRNAs (miR-4443 and mir-3620-5p) were further validated using 4 GBM cell lines. Both miRNAs are predicted to be responsible for TNC and CD209 modulation, respectively. Those genes are known as post-transcriptional target genes for the NF-κB pathway.

Thus, our study revealed, for the first time, that both miR-4443 and mir-3620-5p are upregulated in GBM cell lines after DPG exposure. miR-4443 was first identified by Xun et al. (29) in enterovirus-71-infected cells. In addition, it has been shown that miR-4443 plays a role in acquiring drug resistance in breast cancer (30) and inhibits cell proliferation and metastasis in colon cancer (31). In addition, miR-4443 is decreased in metastatic and serous samples from ovarian cancer (32). In the study of Gao et al. (33), the authors have found that long non-coding RNAs (lncRNAs) MNX1-AS1 were upregulated in GBM tissues and cell lines. The knockdown of MNX1-AS1 significantly inhibited the proliferation, migration, and invasion of GBM cells. In addition, the overexpression of miR-4443 significantly inhibited the expression of MNX1-AS1 and vice versa. Moreover, there was an inverse correlation between the expression levels of MNX1-AS1 and miR-4443 in GBM tissues. The overexpression of miR-4443 also inhibited the proliferation, migration, and invasion of GBM cells. In contrast, the inhibition of miR-4443 reversed the effects of MNX1-AS1 knockdown on GBM cell proliferation, migration, and invasion. MNX1-AS1 promoted the proliferation, migration, and invasion of GBM cells by inhibiting miR-4443.

TNC and CD209 genes play an important role in the progression of GBM by regulating the migration, adhesion, and invasion of tumor cells into adjacent tissues (35, 36). The TNC gene was evaluated in tumor tissues and primary cultures of patients with GBM, and its increased expression was associated with the process of carcinogenesis and invasion (35, 37). A recent survey of tumor tissues from patients with GBM correlated the infiltrative character of GBM malignant cells with an increased expression of CCL15, CCL17, CD209, and TNF-α genes (36). In the GBM cell line (U87MG), CD209 gene interacts with TGF-β1 gene, stimulating cell invasion and metastasis (38). In addition, the results of the cell proliferation assay and wound healing in the present study corroborate with what was observed previously regarding CD209 and TNC genes, both involved in cell metastasis process. Both genes
showed a significant decrease in expression due to the overexpression of miR-4443 and miR-3620, respectively, after the DPG effect in the evaluated GBM cell lines in the study.

Therefore, DPG-modulated miRNAs are involved in the post-transcriptional inhibition of the NF-κB pathway. Interestingly, in a previous study, DPG inhibited the NF-κB pathway by modulation of miR-16 and miR-146a, which inhibited the expression of its target genes IRAK2 and TRAF6, respectively (14). It appears that the antitumor action of DPG can inhibit genes that belong to the NF-κB signaling pathway and genes downstream by the overexpression of miRNAs.

In accordance with the results observed in the present study, another recent study has suggested that DPG has an apoptotic, anti-proliferative, and anti-migratory effect on the melanoma cell line (SK-MEL-28) bearing the BRAF mutation. DPG was also able to inhibit cancer stem-like cells that may cause cerebral tumor formation (39). In addition, DPG treatment has shown that SK-MEL-28 cells also presented a significantly higher level of miR-4443 and miR-3620 expression than control cells. In contrast, their predicted genes, CD209 and TNC, significantly presented reduced mRNA levels after DPG compared to untreated cells. Furthermore, the migration of SK-MEL-28 cells stimulated by 12-O-tetradecanoylphorbol-13-acetate (TPA) was attenuated by adding DPG by wound-healing assay. In addition, the MMP-9 expression level was inhibited by DPG in melanoma cells stimulated by TPA and compared to only TPA-treated cells (39).

Therefore, in the present study, the potential inhibition by DPG was verified on miR-4443 and miR-3620, possible

### TABLE 1 | The most upregulated microRNAs (FC ≥ 2) after dipotassium glycyrrhizinate (DPG) treatment in the glioblastoma T98G cell line by global miRNA microarrays.

| MicroRNAs | FC  | mRNA volume | Target genes (>99%) | Function |
|-----------|-----|-------------|---------------------|----------|
| 1 miR-4448 | 16.70 | 2.01 | CASP4 | Apoptosis—caspace |
| 2 miR-1587 | 3.88 | 3.60 | TNC | Cell adhesion—control of cell growth, migration, and adhesion by the ECM protein |
| 3 miR-3620-5p | 2.04 | 6.68 | TNC | Cell adhesion—control of cell growth, migration, and adhesion by the ECM protein |
| 4 miR-4443 | 2.10 | 7.12 | CD209 | Cell adhesion—dendritic cell surface by leptin C |
| 5 miR-7111-5p | 2.66 | 2.71 | MAP4K1 | Stress response—activator of the stress-induced protein kinase pathway |
| 6 miR-3148 | 6.79 | 2.93 | S100A4 | Miscellaneous—tumor suppressor |

FC, fold change; mRNA volume, \( \sqrt{\text{normalized control value} / \text{normalized DPG value}} \).

*Prediction according to TargetScan database.
therapeutic targets for GBM. In addition, the results obtained in the present study may contribute to the development of future in vivo studies to target GBM cells by DPG, which is a promising approach to restrict tumor cell growth.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

AUTHOR CONTRIBUTIONS

Conception and design: MMO; acquisition of data: GAB, JSS, and JVZ; analyses and interpretation of data: MMO and GAB; statistical analyses: FALM; drafting of the manuscript: MMO; mass spectrometer analyses: POC and AMAPF; TUNEL analysis: GAB and TR; study supervision: MMO. All authors contributed to the article and approved the submitted version.

FUNDING

The financial support provided for this work by the São Paulo Research Foundation (FAPESP) scholarships #2018/05930-0 and grant #2015/03870-1 and by Coordination for the Improvement of Higher Education Personnel (CAPES) scholarship #88887.464813/2019-00 is gratefully acknowledged.
ACKNOWLEDGMENTS

We are thankful to JZ, Verdi Cosméticos LTDa (Joanópolis, São Paulo, Brazil), for the dipotassium glycyrrhizinate donation (chemical abstracts service number 68797-35-3).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2022.819599/full#supplementary-material

Supplementary Figure 1 | Mass spectrum of dipotassium glycyrrhizinate (DPG). The presence of the ion [M-H]^-1 (the anion of the DPG) and the ion [M-2H]^2- is highlighted. The error observed for measuring the ion [M-H]^-1 (DPG anion) was -1.83 ppm.

Supplementary Figure 2 | Identification of microRNAs (miRNAs) with differential expression (DE-miRNAs) in glioblastoma T98G cell line. (A) Scatter plot of 11 DE-miRNAs identified after comparing dipotassium glycyrrhizinate (DGP)-treated and control T98G cell line (among 91 predicted miRNAs as NF-kB regulator genes). The red dots represent those miRNAs that presented |fold change, FC| ≥ 2 and increased volume of mRNA detected and quantified by the Affymetrix GeneChip® Command Console™. The dots above and below the dashed line represent those up- and downregulated miRNAs after DPG treatment, respectively. (B) Volume graph of the most overexpressed miRNAs among the 11 DE-miRNAs in T98G cell line exposure to DPG. Each gray, blue, and red dots represent one DE-miRNA. The red dots represent those miRNAs that presented both [FC ≥ 2] and increased volume of mRNA detected and quantified by the Affymetrix GeneChip® Command Console™ software. The dots above and below the dashed line represent those up- and downregulated miRNAs after DPG treatment, respectively.

Supplementary Table 1 | List of the 91 selected miRNAs predicted as NF-kB modulators and their predicted target genes (above 99%, according to TargetScan database) belonging to the NF-kB signaling pathway.

REFERENCES

1. Hambardzumyan D, Beggars G. Glioblastoma: Defining Tumor Niches. Trends Cancer (2015) 1:252–65. doi: 10.1016/j.trecan.2015.10.009
2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma. N Engl J Med (2005) 352:987–96. doi: 10.1056/NEJMoa043330
3. The Cancer Genome Atlas Research Network. Comprehensive Genomic Characterization Defines Human Glioblastoma Genes and Core Pathways. Nature (2008) 455:1061–8. doi: 10.1038/nature07385
4. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al. Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRα, IDH1, EGFR, and NF1. Cancer Cell (2010) 17:98–110. doi: 10.1016/j.ccr.2009.12.020
5. Snuderl M, Fazlollahi L, Le LP, Nitta M, Zhelyazkova BH, Davidson CJ, et al. Mosaic Amplification of Multiple Receptor Tyrosine Kinase Genes in Glioblastoma. Cancer Cell (2011) 20:810–7. doi: 10.1016/j.ccr.2011.11.005
6. Szerlip NJ, Pedraza A, Chakravarty D, Azim M, McGuire J, Fang Y, et al. Intratumoral Heterogeneity of Receptor Tyrosine Kinases EGFR and PDGFRα Amplification in Glioblastoma Defines Subpopulations With Distinct Growth Factor Response. Proc Natl Acad Sci U.S.A. (2012) 109:3041–6. doi: 10.1073/pnas.1114033109
7. Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, et al. The Somatic Genomic Landscape of Glioblastoma. Cell (2013) 155:462–77. doi: 10.1016/j.cell.2013.09.034
8. Sottoriva A, Spiteri I, Piccirillo SG, Touloumis A, Collins VP, Marioni JC, et al. Intratumor Heterogeneity in Human Glioblastoma Reflects Cancer Evolutionary Dynamics. Proc Natl Acad Sci U.S.A. (2013) 5:4009–14. doi: 10.1073/pnas.1219477110
9. Patel AP, Tirosh I, Trombetta JJ, Shalek AK, Gillespie SM, Wakimoto H, et al. Single-Cell RNA-Seq Highlights Intratumoral Heterogeneity in Primary Glioblastoma. Science (2014) 344:1396–401. doi: 10.1126/science.1254257
10. Ahir BK, Ozer H, Engelhard HH, Lakka SS. MicroRNAs in Glioblastoma Pathogenesis and Therapy: A Comprehensive Review. Crit Rev Oncol Hematol (2017) 120:22–33. doi: 10.1016/j.critrevonc.2017.10.003
11. Kim TM, Huang W, Park R, Park PJ, Johnson MD. A Developmental Taxonomy of Glioblastoma Defined and Maintained by MicroRNAs. Cancer Res (2011) 71:3387–99. doi: 10.1158/0008-5472.CAN-10-4117
12. Henrikson M, Johnsen KB, Olesen P, Pilgaard L, Durox M. MicroRNA Expression Signatures and Their Correlation With Clinicopathological Features in Glioblastoma Multiforme. Neurourol Urodyn (2014) 16:565–77. doi: 10.1007/s00601-014-1809-7
13. Huang SW, Ali ND, Zhong L, Shi J. MicroRNAs as Biomarkers for Human Glioblastoma: Progress and Potential. Acta Pharmacol Sin (2018) 39:1405–13. doi: 10.1038/apss.2017.173
14. Bonafé GA, Dos Santos JS, Ziegler JV, Umezawa K, Ribeiro ML, Rocha T, et al. Growth Inhibitory Effects of Dipotassium Glycyrrhizinate in Glioblastoma Cell Lines by Targeting MicroRNAs Through the NF-kB Signaling Pathway. Front Cell Neurosci (2019) 13:216. doi: 10.3389/fncel.2019.00216
Signaling in Glioblastoma. *Oncotarget* (2015) 6:17805–16. doi: 10.18632/oncotarget.4596
27. Wang H, Pan JQ, Luo L, Ning XJ, Ye ZP, Yu Z, et al. NF-κb Induces miR-148a to Sustain TGF-β/Smad Signaling Activation in Glioblastoma. *Mol Cancer* (2015) 14:2. doi: 10.1186/1476-4598-14-2
28. Wu H, Liu Q, Cai T, Chen YD, Wang ZF. Induction of microRNA-146a is Involved in Curcumin-Mediated Enhancement of Temozolomide Cytotoxicity Against Human Glioblastoma. *Mol Med Rep* (2015) 12:5461–6. doi: 10.3892/mmr.2015.4087
29. Xun M, Ma CF, Du QL, Ji YH, Xu JR. Differential Expression of miRNAs in Enterovirus 71-Infected Cells. *Virol J* (2015) 12:56. doi: 10.1186/s12985-015-0288-2
30. Chen X, Zhong SL, Lu P, Wang DD, Zhou SY, Yang SJ, et al. miR-4443 Participates in the Malignancy of Breast Cancer. *PloS One* (2016) 11:e0160780. doi: 10.1371/journal.pone.0160780
31. Meerson A, Yehuda H. Leptin and Insulin Up-Regulate miR-4443 to Suppress NCOA1 and TRAF4, and Decrease the Invasiveness of Human Colon Cancer Cells. *BMC Cancer* (2016) 16:882. doi: 10.1186/s12885-016-0288-2
32. Ebrahimi SO, Reiisi S. Downregulation of miR-4443 and miR-5195-3p in Ovarian Cancer Tissue Contributes to Metastasis and Tumorigenesis. *Arch Gynecol Obstet* (2019) 299:1453–8. doi: 10.1007/s00404-019-05107-x
33. Gao Y, Xu Y, Wang J, Yang X, Wen L, Feng J. IncRNA MNX1-AS1 Promotes Glioblastoma Progression Through Inhibition of miR-4443. *Oncol Res* (2019) 27(3):341–7. doi: 10.3727/096550418X15228909735079
34. Song YX, Sun JX, Zhao JH, Yang YC, Shi JX, Wu ZH, et al. Non-Coding RNAs Participate in the Regulatory Network of CLDN4 via ceRNA Mediated miRNA Evasion. *Nat Commun* (2017) 8:289. doi: 10.1038/ncomms13725
35. Xia S, Lal B, Tung B, Wang S, Goodwin CR, Laterra J. Tumor Microenvironment Tenascin-C Promotes Glioblastoma Invasion and Negatively Regulates Tumor Proliferation. *Neuro Oncol* (2016) 18:507–17. doi: 10.1093/neuonc/nov171
36. Gabrusiewicz K, Rodriguez B, Wei J, Hashimoto Y, Healy LM, Maiti SN, et al. Glioblastoma-Infiltrated Innate Immune Cells Resemble M0 Macrophage Phenotype. *JCI Insight* (2016) 1:e85841. doi: 10.1172/jci.insight.85841
37. Sivasankaran B, Degen M, Ghaffari A, Hegi ME, Hamou MF, Ionescu MC, et al. Tenascin-C is a Novel RBPJKappa-Induced Target Gene for Notch Signaling in Gliomas. *Cancer Res* (2009) 69:458–65. doi: 10.1158/0008-5472.CAN-08-2610
38. Bryukhovetskiy I, Shevchenko V. Molecular Mechanisms of the Effect of TGF-β1 on U87 Human Glioblastoma Cells. *Oncol Lett* (2016) 12:1581–90. doi: 10.3892/ol.2016.4756
39. Bonafé GA, Santos JS, Ziegler JV, Marson FA, Rocha T, Ortega MM. Dipotassium Glycyrrhizinate on Melanoma Cell Line: Inhibition of Cerebral Metastases Formation by Targeting NF-kB Genes-Mediating microRNA-4443 and microRNA-3620. *Int J Mol Sci* (2022) 23, 7251. doi: 10.3390/ijms23137251